Why Moderna Stock Was Sick on Monday

Already contending with notable drops in COVID cases and fatalities, Moderna (NASDAQ: MRNA) -- a stock closely associated with the pandemic -- suffered a fresh decline on Monday. Bearishness on the company was exacerbated by an analyst's price-target cut that morning, and the shares fell by more than 7% on the day.

The analyst in question was Deutsche Bank's Emmanuel Papadakis, who shaved $20 off his existing price target on Moderna stock for a new level of $155. He is maintaining his hold recommendation on the shares.

Image source: Getty Images.

Source Fool.com